Same Indication

Ipilimumab vs Sitagliptin

Ipilimumab vs Sitagliptin: Overview

This comparison examines the pharmacological differences between Ipilimumab and Sitagliptin.

Mechanism of Action

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Sitagliptin: DPP-4 inhibitor increasing incretin levels.

Pharmacokinetics

Half-life: Ipilimumab — 14.7 days; Sitagliptin — 12.4 hours.

Chemical Properties

Molecular Formula: Sitagliptin — C16H15F6N5O.

Molecular Weight: Sitagliptin — 407.3140 g/mol.

Type: Ipilimumab — Antibody; Sitagliptin — Small molecule.